U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22FN3O3
Molecular Weight 395.4268
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETANSERIN

SMILES

FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2

InChI

InChIKey=FPCCSQOGAWCVBH-UHFFFAOYSA-N
InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)

HIDE SMILES / InChI

Molecular Formula C22H22FN3O3
Molecular Weight 395.4268
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ketanserin is a selective 5HT2A receptor antagonist which was initially developed as an anti-hypertensive medicine. However, now the drug is available as a topical gel formulation for the treatment of wounds, burns, ulcers and anal fissure (Sufrexal brand name). The drug action is explained by its ability to accelerate epithelialization.

CNS Activity

Sources: Hideya Sait, Masaru Minami (1992) 'Antihypertensive Drugs Today', p.194

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.7 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Sufrexal

Approved Use

Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Curative
Sufrexal

Approved Use

Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Curative
Sufrexal

Approved Use

Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Curative
Sufrexal

Approved Use

Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Curative
Sufrexal

Approved Use

Non-neoplastic dermal and uterine cervix ulcers. Traumatic wounds such as decubitus ulcers. Preparation of tissue for grafting and flaps. Uninfected burns. Regeneration of the uterine cervix. Anal fissure
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
193 μg/L
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
110.2 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
127 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
60.7 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
46.1 ng/mL
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14.2 ng/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
71.4 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
198 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
287 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
385.3 ng × h/mL
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
392.7 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
632 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
637 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
855 ng × h/mL
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
265 ng × h/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
279 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
625 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
992 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.8 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.4 h
0.15 mg/kg bw single, intravenous
dose: 0.15 mg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15.6 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18.5 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
29 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
28 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
40 h
40 mg 2 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
39 h
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
16.5 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.8 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16.9 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6.1%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.1%
0.15 mg/kg bw single, intravenous
dose: 0.15 mg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.36%
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
KETANSERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.3%
KETANSERIN plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
10 mg single, intraarterial
Highest studied dose
Dose: 10 mg
Route: intraarterial
Route: single
Dose: 10 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
10 mg single, intravenous
Highest studied dose
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Sedation, Dizziness...
Other AEs:
Sedation (44%)
Dizziness (44%)
Sources:
60 mg 3 times / day multiple, oral
Highest studied dose
Dose: 60 mg, 3 times / day
Route: oral
Route: multiple
Dose: 60 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Fainting, Dizziness...
AEs leading to
discontinuation/dose reduction:
Fainting (10%)
Dizziness (10%)
Fall (20%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 44%
10 mg single, intravenous
Highest studied dose
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Sedation 44%
10 mg single, intravenous
Highest studied dose
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Dizziness 10%
Disc. AE
60 mg 3 times / day multiple, oral
Highest studied dose
Dose: 60 mg, 3 times / day
Route: oral
Route: multiple
Dose: 60 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Fainting 10%
Disc. AE
60 mg 3 times / day multiple, oral
Highest studied dose
Dose: 60 mg, 3 times / day
Route: oral
Route: multiple
Dose: 60 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Fall 20%
Disc. AE
60 mg 3 times / day multiple, oral
Highest studied dose
Dose: 60 mg, 3 times / day
Route: oral
Route: multiple
Dose: 60 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Gastroprokinetic effect and mechanism of SK-896, a new motilin analogue, during the interdigestive period in conscious dogs.
2001
Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice.
2001 Apr
Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies.
2001 Apr
Use of topical ketanserin for the treatment of ulcers in leprosy patients.
2001 Apr-Jun
Blood pressure patterns in pregnant patients on oral ketanserin.
2001 Apr-May
Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity.
2001 Apr-May
Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder.
2001 Aug
In vivo evaluation of 4-[123I]iodo-N-[2[4-(6-trifluoromethyl-2-pyridinyl)-1-piperazinyl]ethyl]benzamide, a potential SPECT radioligand for the 5-HT1A receptor.
2001 Aug
Complex interaction of ergovaline with 5-HT2A, 5-HT1B/1D, and alpha1 receptors in isolated arteries of rat and guinea pig.
2001 Aug
Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors.
2001 Aug
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons.
2001 Aug
Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine.
2001 Aug 1
Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain.
2001 Aug 1
Activation of spinal serotonin(2A/2C) receptors augments nociceptive responses in the rat.
2001 Aug 10
Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion.
2001 Aug 15
Role of 5-HT(2) receptor subtypes in depletion of 5-HT induced by p-chloroamphetamine in the mouse frontal cortex.
2001 Aug 24
Serotonin(2) receptors mediate respiratory recovery after cervical spinal cord hemisection in adult rats.
2001 Dec
Influence of serotonin on the glutamate-induced excitations of secondary vestibular neurons in the rat.
2001 Dec
Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers.
2001 Dec
Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release.
2001 Jan-Feb
Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man.
2001 Jul
Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300.
2001 Jul
Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test.
2001 Jul 13
Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.
2001 Jul-Aug
The effects of hypothyroidism on 5-HT1A and 5-HT2A receptors and the serotonin transporter protein in the rat brain.
2001 Jul-Aug
Platelet 3H ketanserin binding in migraine.
2001 Jun
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
2001 Jun
The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.
2001 Jun
Effect of bile salts on colonic mucus secretion in isolated vascularly perfused rat colon.
2001 Jun
Pharmacological evaluation of (+)-2- [123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors.
2001 Jun 29
Could the 5-HT1B receptor inverse agonism affect learning consolidation?
2001 Mar
Conditioned antinociception and freezing using electrical stimulation of the dorsal periaqueductal gray or inferior colliculus as unconditioned stimulus are differentially regulated by 5-HT2A receptors in rats.
2001 May
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
2001 May 18
Antidepressant-like effects of aniracetam in aged rats and its mode of action.
2001 Nov
Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia.
2001 Nov
Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.
2001 Nov 6
Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane.
2001 Oct
Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat.
2001 Oct
Physiology and pathophysiology of the serotonergic system and its implications on mental and physical performance. Part II.
2001 Oct
Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors.
2001 Oct
Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists.
2001 Oct
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
2001 Oct
Neuroepithelial bodies in mammalian lung express functional serotonin type 3 receptor.
2001 Oct
Ketanserin attenuates the behavioural effects of corticosterone: implications for 5-HT(2A) receptor regulation.
2001 Oct 5
Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743.
2001 Oct 5
On the role of serotonin2A/2C receptors in the sensitization to cocaine.
2001 Sep
Prostaglandins may participate in opioidergic and cholinergic control of the diurnal changes of tuberoinfundibular dopaminergic neuronal activity and serum prolactin level in ovariectomized, estrogen-treated rats.
2001 Sep 1
Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons.
2001 Sep 1
Stimulation of 5-HT2 receptors in the nucleus tractus solitarius enhances NMDA receptor-mediated reflex-evoked bradycardiac responses in the rat.
2001 Sep 17
Effects of 5-HT(2) receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice.
2001 Sep 21
Patents

Sample Use Guides

Apply a thin layer twice a day (topical gel) or use one applicator every 24 hours at night before bed for two weeks (vaginal application). In case of anal fissure, apply a small amount of the gel digitally in the anus area 3 times a day, preferably after bowel movement and cleaning the area with soap and water. The minimum recommended treatment time is 15 days.
Route of Administration: Topical
2% and 20% topical ketanserin significantly accelerates both the vascular epithelial rates of wound healing in full-thickness nonpathologic skin wounds.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:48:17 GMT 2025
Edited
by admin
on Wed Apr 02 09:48:17 GMT 2025
Record UNII
97F9DE4CT4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KETANSERIN
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
R-41,468
Preferred Name English
KETANSERIN [USAN]
Common Name English
ketanserin [INN]
Common Name English
3-(2-(4-(P-FLUOROBENZOYL)PIPERIDINO)ETHYL)-2,4-(1H,3H)-QUINAZOLINEDIONE
Common Name English
KETANSERIN [MART.]
Common Name English
2,4(1H,3H)-QUINAZOLINEDIONE, 3-(2-(4-(4-FLUOROBENZOYL)-1-PIPERIDINYL)ETHYL)-
Systematic Name English
Ketanserin [WHO-DD]
Common Name English
KETANSERIN [MI]
Common Name English
R-41468
Code English
Classification Tree Code System Code
WHO-VATC QD03AX90
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
WHO-ATC C02KD01
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
NCI_THESAURUS C66885
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
WHO-VATC QC02KD01
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
Code System Code Type Description
IUPHAR
88
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
277-680-2
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
DRUG CENTRAL
1524
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
NCI_THESAURUS
C604
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
DRUG BANK
DB12465
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL51
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
CHEBI
6123
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
SMS_ID
100000082848
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
INN
5087
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
MESH
D007650
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
WIKIPEDIA
KETANSERIN
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
FDA UNII
97F9DE4CT4
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
MERCK INDEX
m6614
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID3023188
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
EVMPD
SUB08366MIG
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
CAS
74050-98-9
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
PUBCHEM
3822
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY
RXCUI
6131
Created by admin on Wed Apr 02 09:48:17 GMT 2025 , Edited by admin on Wed Apr 02 09:48:17 GMT 2025
PRIMARY RxNorm
Related Record Type Details
LABELED -> NON-LABELED
TARGET -> INHIBITOR
Binding Assay
IC50
SALT/SOLVATE -> PARENT
OFF-TARGET->INHIBITOR
BINDING
IC50
TARGET -> INHIBITOR
BINDING
IC50
TRANSPORTER -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY